BETA: Please send your feedback!
Seattle Genetics
SGEN:NAS
Biotechnology
$0
MID cap
$112.50
(-1.48%)
0.97%
since start of 2019
-60.21
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1997
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
website
Headquarters
Executives
| Name | Title | Gender |
| Jean I. Liu | Executive VP-Legal Affairs & General Counsel | Female |
| Vaughn B. Himes, PhD | Chief Technology Officer | Male |
| Perry Fell, PhD, MBA | Founder | Male |
| Clay B. Siegall, PhD | Chairman, President & Chief Executive Officer | Male |
| Eric L. Dobmeier | Chief Operating Officer | Male |
| Todd E. Simpson, CPA | Chief Financial Officer | Male |
| Jonathan Drachman, MD | Chief Medical Officer, EVP-Research & Development | Male |
| Christopher Pawlowicz | Executive Vice President-Human Resources | Male |
| Elaine Waller, PhD | Executive Vice President-Regulatory Affairs | Female |
| Peggy Pinkston | Executive Director-Investor Relations | Female |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
Seattle Genetics - Competitors and Related Companies
How Seattle Genetics stacks up to its peers in the Biotechnology industry or with competing business segments.
Seattle Genetics
SGEN:NAS
Biotechnology
$0
MID cap
$112.50
(-1.48%)
0.97%
since start of 2019
-60.21
Spectrum Pharmaceuticals
SPPI:NAS
Biotechnology
$1.04bn
MID cap
$9.99
(-0.35%)
0.09%
since start of 2019
-8.84
ImmunoGen
IMGN:NAS
Biotechnology
$559.11mm
SMALL cap
$3.73
(-0.06%)
-0.22%
since start of 2019
-3.70
Biogen
BIIB:NAS
Biotechnology
$53.24bn
MEGA cap
$295.03
(-2.17%)
-0.03%
since start of 2019
10.48
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
$101.49bn
MEGA cap
$62.29
(0.20%)
0.19%
since start of 2019
17.89
GlaxoSmithKline
GSK-GB:LON
Pharmaceuticals: Major
$114.49bn
MEGA cap
$46.24
(0.09%)
0.22%
since start of 2019
19.70